![Virtual Booth](https://www.pharmacompass.com/image/vb/vb-orange-btn.png)
![Minakem Generic APIs](https://www.pharmacompass.com/image/flap/minakem-header-desktop-w27gif-57924.gif)
![Minakem Generic APIs](https://www.pharmacompass.com/image/flap/minakem-header-mobile-w27gif-62411.gif)
Active Filter(s):
Details:
Currently, the company caters to anti-infective and pain-management therapeutic areas and has a pipeline of products to enter into the cardio/diabetic and ortho/gynaecology segments, including Veriaz.
Lead Product(s): Azithromycin
Therapeutic Area: Infections and Infectious Diseases Product Name: Veriaz
Highest Development Status: Approved Product Type: Small molecule
Partner/Sponsor/Collaborator: Aurobindo Pharma Limited
Deal Size: $22.5 million Upfront Cash: Undisclosed
Deal Type: Acquisition March 28, 2022